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Abstract   28 
An extrusion based 3D printer was used to fabricate paracetamol tablets with different geometries 29 
(mesh, ring, and solid) from a single paste-based formulation formed from standard pharmaceutical 30 
ingredients. The tablets demonstrate that tunable drug release profiles can be achieved from this single 31 
formulation even with high drug loading (>80% w/w). The tablets were evaluated for drug release using 32 
a USP dissolution testing type I apparatus. The tablets showed well-defined release profiles (from 33 
immediate to sustained release) controlled by their different geometries. The dissolution results showed 34 
dependency of drug release on the surface area/volume (SA/V) ratio and the SA of the different tablets. 35 
The tablets with larger SA/V ratios and SA had faster drug release. The 3D printed tablets were also 36 
evaluated for physical and mechanical properties including tablet dimension, drug content, weight 37 
variation, breaking force and were within acceptable range as defined by the international standards 38 
stated in the United States Pharmacopoeia. X-Ray Powder Diffraction, Differential Scanning 39 
Calorimetry, and Attenuated Total Reflectance Fourier Transform Infrared Spectroscopy were used to 40 
identify the physical form of the active and to assess possible drug-excipient interactions. These data 41 
again showed that the tablets meet USP requirement. These results clearly demonstrate the potential of 42 
3D printing to create unique pharmaceutical manufacturing, and potentially clinical, opportunities. The 43 
ability to use a single unmodified formulation to achieve defined release profiles could allow, for 44 
example, relatively straightforward personalization of medicines for individuals with different 45 
metabolism rates for certain drugs and hence could offer significant development and clinical 46 
opportunities. 47 
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1. Introduction 54 
Personalised medicine is defined as a customization of health care to individual patients through linking 55 
diagnostics and treatments with genetic testing and emerging technologies such as proteomics and 56 
metabolomics analysis (1). The main advantages of this approach, are to increase the effectiveness of 57 
the prescribed treatment regimen and to minimize their adverse effects such as those linked to 58 
overdosing of drugs with a narrow therapeutic index such as digoxin and anti-clotting agents (2). In the 59 
context of solid oral dosage forms, conventional large-scale tableting manufacturing methods are 60 
clearly unsuited to personalised medicine and in addition, provide restrictions on the complexity 61 
achievable in the dosage form in terms of, for example, tablet geometry, drug dosage, distribution and 62 
combinations.  3D printing offers the potential for the manufacture of bespoke solid oral dosage forms. 63 
3D printers also offer the possibility of reducing the number of manufacturing steps as currently used 64 
in traditional tablet production process, such as powder milling, wet granulation, dry granulation, tablet 65 
compression, and coating and the potential for rapid formulation development with limited quantities 66 
of active ingredients as available in early drug development (3, 4) 67 
3D printing is hence a potentially significant platform that can produce viable solid dosage forms in 68 
complex geometries in a programmed, controlled manner and with accurate drug loading (5-8). Many 69 
believe, that 3D printers could play an important role in the development of personalised unit dose 70 
medication for targeting the specific needs of individual patients and treatments (5, 6, 9). In envisaging 71 
how such an approach could be taken to the practical manufacture of dosage forms it would clearly 72 
simplify matters greatly if the formulation (or ‘ink’ in 3D printer terms) could be kept as simple as 73 
possible, with little need for the use of multiple formulations that must be mixed precisely in situ within 74 
the 3D printer. Such a complex mixing approach would greatly complicate supply chains, increase 75 
quality control difficulties and subsequently raise regulatory barriers even higher than might be 76 
expected for such a new approach to manufacture. We propose, and demonstrate here, that the required 77 
need for personalization in terms of drug release profile can be achieved by the control of tablet 78 
geometry alone from a single formulation. Such an approach, we propose would significantly increase 79 
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the likelihood of 3D printing being adopted for the development and manufacture of personalised 80 
dosage forms. 81 
Paracetamol is commercially available in many different dosage forms including; tablets, capsules, 82 
suspensions, suppositories, and intravenous solutions and is commonly used to treat mild to moderate 83 
pain caused by headaches, toothache, sprain, or strains (4). Here, paracetamol was chosen as a well-84 
known freely available drug suitable for a proof of concept study. The common paracetamol doses 85 
available range from 300 to 500 mg, although 1000 mg is also available in some regions. Therefore, 86 
customizing of paracetamol effect/release (plasma peak levels) while prolonging its action by using 87 
different tablet geometries is potentially desirable (10). The effect of dosage form geometry on drug 88 
release for controlled release has been reported (10-12). Previously work has also been done on 3D 89 
printing of paracetamol formulations primarily using Fused Deposition Modelling (FDM) 3D printing 90 
(4, 13-18). However, the high extrusion temperature used in FDM  (≥120 °C) narrows the potential 91 
active ingredient library to include only heat stable actives (4). Other possible 3D printing methods like 92 
Stereolithography (SLA) and ink-jet printing currently use excipients that are not generally recognized 93 
as safe (GRAS) (13).  94 
Different types of 3D printer are commercially available including the aforementioned FDM, Inkjet, 95 
Selective Laser Sintering (SLS) and SLA, and significant work has been done in the area of drug 96 
delivery using these approaches (7, 12-14, 19-23). Published research regarding 3D printing techniques 97 
to achieve controlled drug release include; Sadia and co-workers, who created multi-channelled tablets 98 
using FDM for a Biopharmaceutics Classification System (BCS) class IV drug, hydrochlorothiazide 99 
(24). Also Yang et al. used FDM to print tablets with differing internal scaffold structures to control 100 
ibuprofen release (25). SLS has been used by Fina et al. to create orally-disintegrating paracetamol 101 
tablets whose drug release depending upon the printing speed (17). We have also previously 102 
demonstrated the flexibility afforded by 3D extruding semi-solid formulations at ambient conditions 103 
using compendia grades available to form tablets to achieve controlled drug release (5, 6, 26). Whilst 104 
extrusion-based 3D printing avoids the heat stress associated with other techniques it has some 105 
disadvantages including; relatively low spatial resolution compared to other 3D printing approaches, 106 
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and that it may not be suitable for water-sensitive materials (degradation unless solvent or binder other 107 
than water is used). In this research the drying temperature was set at 80 °C to accelerate the drying time 108 
of the printed tablets (4). However, lower temperatures in a range of 40-60 °C can be employed, as is 109 
commonly used in drying oral solid dosage form but this leads to longer drying times. The aim of this 110 
work is to introduce extrusion-based 3D printer for the first time as a capable tool to print different 111 
geometries with meaningful drug loading that can be used to define drug release profiles. 112 
2. Materials and methods 113 
2.1. Materials 114 
Paracetamol, and polyvinylpyrrolidine (PVP K25) were supplied by Sigma–Aldrich (Gillingham, UK). 115 
Croscarmellose sodium (NaCCS) (Primellose®) was kindly supplied as a gift from DFE Pharma. Starch 116 
was kindly supplied by Colorcon®. Milli-Q water (resistivity 18.2 MΩ cm) was used for all 117 
formulations and solutions. All other reagents were of either HPLC or analytical grade. 118 
2.2. Methods  119 
2.2.1. Design of paracetamol tablets 120 
A strategy of controlling the geometry to be generally oval shaped (easy to swallow) for the 3D printed 121 
tablets was chosen (Fig. 1). A tablets normal solid tablet geometry was altered to also produce an oval 122 
ring and an oval tablet with an internal mesh or lattice-like structure. The mesh tablets which were 123 
printed in 13 layers in an external oval ring (formed from two or three printed ovals) and an internal 124 
cross-lattice mesh format. There was an internal gap of 0.4mm between the two printed oval walls of 125 
layers 2-12 (Fig.1), with the top (layer 13) and bottom (layer 1) layers having three oval walls printed 126 
around the mesh structure with no gap between them to ensure tablet integrity. The ring tablets was 127 
simply produced by printing oval walls of different dimensions until the ring like structure was 128 
achieved. The outer dimensions of the designed oval tablets was 15 mm length × 8 mm width × 3.2 mm 129 
height for the solid tablets, 4.8 mm height for the ring tablets, and 5.2 mm height for the mesh tablets. 130 
The geometry of the tablets was designed using a 3D drawing package (BioCAD, regenHU Villaz-St-131 
Pierre, Switzerland) with the aim of keeping the tablet weight constant across the three geometries.  132 
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2.2.2. 3D printing process of paracetamol tablets 133 
Twelve grams of ground paracetamol and the required excipient powders (starch, PVP K25, and 134 
NaCCS) were mixed using a mortar and pestle for 10 min. 4.5 ml of Milli-Q water (resistivity 18.2 MΩ 135 
cm) was added and the powder was mixed to form a paste according to the formulae shown in Table I.  136 
2.2.3. Extrusion based 3D printing process  137 
A plastic 20 cm3 syringe (Optimum® syringe barrels, Nordson EFD) was used to fill the paste into the 138 
syringe cartridge in the 3D printer (regenHU 3D). A stopper was fixed into Luer-Lock thread at the top 139 
end of the barrel after the filling process to avoid any unintentional leakage of paste from the cartridge 140 
showed in figure 2. Once ready for printing, the stopper was removed, and the required nozzle 141 
(Optimum® SmoothFlow™ tapered dispensing tips, 0.6 mm internal diameter (ID) Nordson EFD) 142 
installed. The filled cartridge was then installed into the printer head and the paste was extruded layer 143 
by layer until the desired tablet dimension was reached (Fig. 2). The 3D printed tablets were left on a 144 
heated printing platform (80 °C) overnight for complete drying. The tablets were stored in a sealed 145 
desiccator stored in a cool and dry location. The following printing parameters were used; tip diameter 146 
0.6 mm, printing speed = 6 mm/sec, printing pressure = 1.8 bar, number of printed layers = 13 for mesh 147 
tablets, 12 for ring tablets, and 8 for solid tablets. The tablet outer dimensions were kept the same but 148 
the geometries were varied using functions in BioCAD software. The tablet weights were kept constant 149 
within a measured range of 308.01 ± 4.52 mg by adjusting the printed tablet height.  150 
2.2.4. Dissolution studies 151 
In vitro drug release studies of the paracetamol 3D printed tablets were performed using a USP Type I 152 
apparatus (rotation speed at 30 rpm, 900 ml phosphate buffer, pH 6.8 as the dissolution media at 37 ± 153 
0.5 °C). 5.0 ml samples were withdrawn at 5, 10, 15, 30, 60, 120, 240, 360, 480, 600, and 720 min. The 154 
samples were centrifuged and 0.5 ml from the supernatant was drawn and diluted to 10 ml using the 155 
dissolution medium. The samples were analysed with a UV–vis spectrophotometer (Cary® 50 UV-vis 156 
spectrophotometer) at a λ max of 243 nm. Drug dissolution studies were conducted in sextuplicate and 157 
the average of percentage of cumulative drug release as a function of time was determined. Although 158 
the USP monograph specifications for paracetamol tablets dissolution testing state that the dissolution 159 
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rotation should be 50 rpm, a speed of 30 rpm was chosen to ensure that the tablet disintegration occurred 160 
mainly due to the effect of disintegrants rather than effects caused by basket rotation. 161 
2.3. Characterization techniques 162 
2.3.1. X-Ray Powder Diffraction (XRPD) 163 
The XRPD patterns of pure paracetamol, excipients (PVP K25, NaCCS, and starch) and paracetamol 164 
formulation powder (powder mixture after tablet ground into powder) were obtained at room 165 
temperature using an X'Pert PRO (PANalytical, Almelo, Netherlands) setup in reflection mode using 166 
Cu Kα1 (lambda =1.54 Å) operating in Bragg–Brentano geometry. The generator voltage was set to 40 167 
kV and the current to 40 mA and the samples were scanned over 2θ range of 5° until 30° in a step size 168 
of 0.026°. 169 
2.3.2. Attenuated Total Reflectance Fourier Transform Infrared Spectroscopy (ATR-FTIR) 170 
Infrared spectra of pure paracetamol, excipients powders (PVP K25, NaCCS, and starch) and 171 
paracetamol formulation powder (powder mixture after tablet ground into powder) were obtained using 172 
an ATR-FTIR (Agilent Cary 630 FTIR) spectrometer. 173 
2.3.3. Differential Scanning Calorimetry (DSC) 174 
The DSC measurements were performed on a TA Instruments' DSC Q2000 coupled to Universal 175 
Analysis 2000 with a thermal analyser. DSC analysis on such drug-excipient mixtures were obtained 176 
by grinding paracetamol tablets and sieving the powders (<150 µm). Accurately weighed samples of 3-177 
5 mg were placed and sealed in aluminium pans. The scans were performed under nitrogen flow (50 178 
mL/min) at a heating rate of 10° C/min from 35° C to 200° C. An empty sealed aluminium pan was 179 
used as a reference. 180 
2.4. Physical properties of paracetamol immediate release 3D printed tablets 181 
2.4.1. Dimension of paracetamol 3D printed tablets 182 
To confirm the tablet size reproducibility, six tablets from each geometry were measured using Vernier 183 
callipers and their average values calculated. 184 
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2.4.2. Weight variation and drug content in the final tablet 185 
Six paracetamol 3D printed tablets (from each geometry) were individually weighed and their average 186 
weight calculated. The individual tablet total weight deviation (%) was calculated. Paracetamol content 187 
in the final tablet was measured as follows; from each batch, 10 paracetamol tablets were weighed and 188 
crushed into powder. A quantity of paracetamol formulation powder equivalent to 0.25g of paracetamol 189 
was weighed and transferred into a 1000 ml volumetric flask. 900 ml of dissolution medium was added 190 
to the flask and placed on a stirrer for 4hrs. 5.0 ml of samples were withdrawn and centrifuged. 0.5 ml 191 
from the supernatant was drawn and diluted to 10 ml using the dissolution medium. The samples were 192 
analysed with a UV–vis spectrophotometer (Cary® 50 UV-vis spectrophotometer) at a λ max of 243 193 
nm. Content uniformity studies were conducted in triplicate and the average of percentage of 194 
paracetamol content was determined. 195 
2.4.3. Breaking force 196 
Six paracetamol 3D printed tablets (from each geometry) were randomly selected and tested for 197 
breaking force using a hardness tester (Hardness tester C50, I Holland Ltd., Holland). The breaking 198 
force values were recorded in N (Newton) units and the tensile strength values were calculated using 199 
equation 1 (27, 28). The tablet breaking force test was done parallel to the longest axis of the 200 
paracetamol tablets. 201 
σf = 3FL/2bd2                                                                                                                                      Eq. 1 202 
Where σf is the tensile fracture strength of the tablet, F is the breaking force, L is the tablet length, b is 203 
the tablet width and d is the tablet thickness. 204 
2.4.4. Friability 205 
Ten paracetamol 3D printed tablets (from each geometry) were selected randomly and the tablets were 206 
accurately weighed (initial weight). The tablets were placed in a friability tester and rotated at a constant 207 
speed of 25 rpm for a period of 4 min in Erweka friabilator. The tablets were cleaned of any loose dust 208 
and reweighed (final weight) and the weight loss % (friability) calculated. 209 
3. Results and discussion 210 
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3.1. Tablet printing 211 
Batches of tablets were printed following the method outlined in Figure 2. Examples of printed tablets 212 
are shown in Figure 3. 213 
3.2.  In vitro drug dissolution 214 
Dissolution data from the paracetamol tablets (Fig. 4) showed that the different tablets geometries with 215 
different height but similar dimension and total weight and dose (Tables IV and V) gave distinct release 216 
profiles. For the paracetamol mesh tablets, more than 70 % of the drug was released within the first 15 217 
minutes. In contrast, only 25 % and 12 % of the drug was released in the same period from the ring and 218 
the solid paracetamol tablets, respectively. This indicates that the tablet surface area showed an 219 
influence on drug release. Apart from surface area exposed to solution the drug release is also impacted 220 
by the inclusion of the disintegrant, NaCCS, which rapidly absorbs water and swells leading to rapid 221 
disintegration. For the mesh tablets with the increased surface means that water absorption takes place 222 
more rapidly than for the ring and solid tablets (Fig. 4).  223 
The drug release from the 3D printed tablets correlates with the SA/V ratios, the higher the SA/V ratio 224 
value, the faster the drug release (Table II). This trend has also been reported by other researches (10, 225 
11, 29). Goyanes et al., showed the effects of SA/V ratios of different geometries on paracetamol release 226 
from tablets prepared by hot melt extrusion (HME) (11). Also in the same study, the authors showed 227 
that the drug release was independent of the surface area (11). Research done by Yi et al., demonstrated 228 
that the drug release from poly lactic-co-glycolic acid/ polycaprolactone/5-Fluorouracil (PLGA/PCL/5-229 
FU) patches was dependent on the changes of SA produced by geometric modifications (12). The 230 
authors then concluded that the tendency of slowing drug release corresponded to a decrease in the 231 
SA/V ratio (12). Furthermore, Gökçe et al., studied the influence of tablet SA/V ratio of two different 232 
geometries (cylinder and hexagonal) of the lipophilic matrix tablets of metronidazole prepared by 233 
Cutina HR (hydrogenated castor oil) (10). They found that the tablets with the highest release rates for 234 
both geometric shapes reflecting the highest surface area and the lowest SA/V ratio (10).  Kyobula et 235 
al. showed that hot melt 3D inkjet printing can be used to manufacture complex and variable 236 
honeycomb geometry tablets for the controlled loading and release of the drug fenofibrate. In this case 237 
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the surface area and wettability of the tablet were shown to influence to the observed sustained drug 238 
release profiles (5). Hence, as can reasonably be expected, we can conclude that the tablet geometry 239 
and surface area generally have an effect on drug release behaviour and are parameters that can be 240 
manipulated to control drug release, even in formulations with additives such as a swellable 241 
disintegrant, as here. The higher the SA and SA/V ratio values the faster the drug release is from the 242 
3D printed tablets (Fig. 4 and Table II).  243 
The demonstrated ability to use a single unmodified formulation to achieve defined release profiles 244 
presents opportunities to optimize or personalize medicines during formulation development and in 245 
clinical use. For example, relatively straightforward personalization of medicines would be possible for 246 
individuals with different metabolism rates due to their genetic makeup (26) for certain drugs and hence 247 
could address issues where people who metabolize drugs slowly may accumulate a toxic level of a drug 248 
in the body or in others who process a drug quickly and never have high enough drug concentrations to 249 
be effective. 250 
3.3. Drug release kinetics  251 
To further understand the drug release mechanisms displayed by the different geometries, the modes of 252 
release of paracetamol over 12 hours at a buffer pH 6.8 was modelled using Zero order, First order, 253 
Higuchi, and Korsmeyer–Peppas models (30, 31). According to fitted r2 values, the mesh and ring 254 
tablets were best fitted by the first order equation (i.e., log cumulative percentage of drug remaining is 255 
proportional to the time) (32) and the solid tablets were best fitted by the Higuchi model (i.e., cumulative 256 
percentage drug release versus square root of time) (32) with r2 values of 0.77, 0.97 and 0.99, 257 
respectively (Table III). The equation reveals n values (as in Eq. (2)) of 0.25 for mesh tablets, 0.44 for 258 
ring tablets and 0.56 for solid tablets.  259 
Mt/M∞=Ktn                (2) 260 
Where Mt/M∞ is the fraction of drug released at time t, K is the release rate constant and the release 261 
exponent (32, 33). 262 
The above results suggest that the drug is released primarily by Fickian diffusion through a gel layer 263 
formed by the amylose in the added starch. Amylose is known to absorb water, swell and then form a 264 
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gel layer (34). The drug release from the mesh tablets was faster than the drug release from the other 265 
geometries (ring and solid). This is, we propose, related to the larger surface area (mesh>ring>solid) 266 
and the more easily disrupted geometry of the mesh tablets where the chance to form a stable gel layer 267 
and hence retard drug release is inhibited. The disintegrants (the amylopectin (insoluble component 268 
found in the starch that can absorb water, swell and act as disintegrant) and NaCCS)) work to weaken 269 
and disrupt the formed gel layer in the mesh tablets. In case of ring and solid tablets the geometry is 270 
more compact with a smaller surface area and less exposure to the dissolution medium than mesh tablets 271 
so the disintegration rate is reduced and there is an increased time to form a gel layer and hence 272 
retardation of drug release (solid>ring>mesh). 273 
3.4. XRPD 274 
XRPD of the pure paracetamol, excipients (PVP K25, NaCCS, and starch) and paracetamol formulation 275 
powder (powder mixture after tablet ground into powder) was done to investigate any potential changes 276 
in physical form of the active on printing (Fig. 5 and 6). The Bragg peaks observed from the pure 277 
paracetamol (as received) match the Bragg peaks of paracetamol (calculated) reported in the Cambridge 278 
Structural Database (CSD) (Fig. 5). 279 
The results in figure 6 show that the paracetamol (non-ground and ground powder) exhibited multiple 280 
sharp Bragg peaks in their XRPD patterns related to their crystalline nature. The post-printing XRPD 281 
data show the same Bragg peaks for the paracetamol. There was, therefore no evidence of a change in 282 
physical form (Form I) for the paracetamol in this formulation fabricated using extrusion based 3D 283 
printing. We believe that a portion of the paracetamol powder could have dissolved after addition a 284 
significant quantity of water (4.5 ml) into total paracetamol dry formulae (12 g) (paracetamol solubility 285 
12.78 g/l /20 °C) (34) as the whole mixture formed a paste, however this must have recrystallized back 286 
into form I if this had occurred. The XRPD data from figure 6 also did not show evidence of 287 
incompatibility between the active and the chosen additives (PVP K25 (10 % w/w), starch (8.33 % 288 
w/w) and NaCCS (0.63 % w/w)) in the 3D printed tablets. 289 
3.5.  ATR-FTIR 290 
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Infrared spectral data show that the characteristic peaks positions remained unchanged from the 291 
paracetamol powder to the formulation, indicating that there were no detectable interactions between 292 
paracetamol (81 % w/w) and the chosen excipients (PVP K25 (10 % w/w), starch (8.33 % w/w) and 293 
NaCCS (0.63 % w/w)) in the tablets (Fig. 7). 294 
3.6.  DSC 295 
DSC analysis was performed to explore potential incompatibility between the active and added 296 
excipients and the stability of drug crystallinity after the 3D printing process (grinding, mixing, paste 297 
formulation and drying process on a hot plate heated at 80 °C). The DSC data from figure 8 shows that 298 
the pure powder of paracetamol melts at 169.7 °C confirming the presence of form I (4, 35, 36) while 299 
the pure powder of PVP K25 shows a glass transition (Tg) around 155 °C (4, 37). The same figure also 300 
shows clear evidence of an endothermal event (melting point) at 169.24 °C from the printed paracetamol 301 
formulation, indicating that the active is still in a crystalline form, specifically form I. From the above 302 
results and discussions, we found that DSC thermogram of paracetamol formulation powder after 303 
grinding, blending, printing, and post-printing processes with the excipients; starch, PVP K25 and 304 
NaCCS did not show significant changes in peak placement apart from the peak depression and 305 
reduction caused by the presence of the polymer in the formulation in comparison to the peak obtained 306 
from the pure paracetamol powder and again suggesting compatibility of the excipients.  307 
3.7.  Physical properties  308 
The 3D printed tablets were evaluated for weight variation, content uniformity, breaking force, friability 309 
and tablet dimensions.  310 
3.7.1. Tablet’s shape and dimension  311 
Table IV confirms that the tablet dimensions were reproducible and comparable with the designed 312 
tablet’s size and dimension and with the tablet size reported in the literature prepared by conventional 313 
tableting press machines (38-40). 314 
3.7.2. Weight variation 315 
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The paracetamol 3D printed tablets showed an acceptable percentage weight variation (table V) and, 316 
therefore, comply with the USP specification for uncoated tablets (±7.5% for average weight of tablets 317 
130 – 324 mg) (41, 42). The paracetamol content in the final tablets was also assessed and found to be 318 
103.2 % ±1.1 for the mesh tablets, 104.0 % ±1.1 for the ring tablets and 103.1 % ±1.5 % for the solid 319 
tablets 320 
3.7.3. Breaking force   321 
Table VI shows the 3D printed tablets breaking forces (kg and N), and the tensile fracture strength. 322 
Tensile fracture strength of the paracetamol flat faced oval tablets were calculated (28). In a 323 
conventional tableting press compression forces can be used to control the physical properties of the 324 
final tablet, where a breaking force value of 4kg is the minimum satisfactory measurement (26, 43). 325 
Measured breaking force measurements were within the accepted range of 8.69-9.56 kg for the solid 326 
tablets but failed to reach the minimum satisfactory value for the mesh and ring tablets (table VI). It is 327 
clear that as compression force is not part of 3D printing process that the same opportunity to manipulate 328 
tablet hardness in this way does not exist and rather the formulation composition, solidification/drying 329 
process and the type of printer employed are critical factors. Clearly, further work beyond the scope of 330 
this paper is required in this area, however, from a subjective and qualitative assessment, the ring and 331 
mesh paracetamol 3D printed tablets appear to be quite robust and are able to tolerate a reasonable 332 
amount of rough handling. For example, they could be dropped onto a hard surface from a height of 333 
around 15 cm without observable damage. In addition, such tablets could be considered for manufacture 334 
close to the patient where traditional wear factors such as chipping, capping, and abrasion which 335 
normally occurred during manufacturing, packaging, and shipping processes are not relevant.  336 
Friability   337 
This is a USP test used to determine a tablets resistance to abrasion, capping, and chipping occurred 338 
during manufacturing, packaging, and shipping processes. All paracetamol 3D printed tablets of 339 
different geometries showed a satisfactory percentage of weight loss ≤ 1 % of the tablet weight (table 340 
VII) and, therefore, the tablets meet USP specifications (44).  341 
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4. Conclusions 342 
Extrusion based 3D printing of different paracetamol tablet geometries with a high drug loading (81 % 343 
w/w) was successfully demonstrated. The mesh-geometry 3D printed tablets released more than 70 % 344 
of the active within 15 min achieving immediate release mesh shaped tablets. In contrast, only 25 % 345 
and 12 % of the drug was released in the same period from the ring and the solid paracetamol tablets, 346 
respectively, effectively demonstrating sustained release. Drug release from the tablets showed a clear 347 
dependency on the SA/V ratio. XRPD, FTIR and DSC data show that the paracetamol form was 348 
unaffected by the printing and that there were no detectable interactions between the paracetamol and 349 
the chosen excipients (Starch, PVP K25 and NaCCS). The 3D printed paracetamol tablets were also 350 
evaluated for weight variation, drug content in the final tablets, hardness, friability, and tablet 351 
dimensions and were within acceptable range as defined by the international standards stated in the 352 
USP. This work again validates that the extrusion-based 3D printing process is capable of producing 353 
viable tablets from materials having compendia grades available for pharmaceutical applications. More 354 
importantly this work demonstrates for the first time the application of extrusion-based printing for 355 
tailoring of drug release from a single formulation through control of only tablet geometry the first. We 356 
believe this is a significant step forward in the potential wider take up of 3D printing for the manufacture 357 
of medicines, particular in the areas of clinical development and personalised medicines. With this 358 
principal demonstrated, it becomes possible to envisage control of drug release and dose (through 359 
dosage form size) on an individual basis using a 3D printer, without the need for forming complex 360 
mixtures from different formulation ‘cartridges’. This would greatly simplify potential supply chains 361 
of formulation inks and the quality control of the printed product. 362 
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List of figure captions 522 
21 
 523 
Fig. 1. Schematic structural diagram of paracetamol 3D printed tablets with different geometric 524 
shapes; mesh, ring and solid tablets. 525 
 526 
Fig. 2. Schematic diagram of cartridge/barrel tool filling process. 527 
22 
 528 
Fig. 3. The regenHU 3D printer (left), and image of paracetamol tablets 15.35 mm length × 8.41 mm 529 
width × 3.44 mm height for solid tablets, and 15.24 mm length × 8.41 mm width × 4.8 mm height for 530 
ring tablets and 15.22 mm length × 8.48 mm width × 5.46 mm height for mesh tablets (average, n = 6) 531 
(right). 532 
 533 
23 
Fig. 4. In vitro cumulative paracetamol release profiles from three different geometries; mesh, ring 534 
and solid paracetamol tablets, n = 6 (the printed tablets have different height but similar dimension 535 
and total weight and dose). 536 
 537 
Figure 5. XRPD patterns of the calculated (top) and reference (measured) paracetamol. 538 
 539 
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 540 
Figure 6. XRPD patterns of paracetamol powder (non-ground and ground Form I) (left), paracetamol 541 
powder (ground Form I), paracetamol formulation, starch, PVP K25, NaCCS and Brass (sample 542 
holder) (right). 543 
 544 
 545 
25 
Figure 7. FTIR spectra of paracetamol powder (ground Form I) and paracetamol formulation (left), 546 
starch, PVP K25, NaCCS (right). 547 
 548 
Figure 8. DSC thermograms of pure paracetamol, paracetamol formulation, starch, PVP K25, and 549 
NaCCS. 550 
 551 
List of tables 552 
Table I. The percentage composition of various ingredients in paracetamol formulation feed stock. 553 
Name of 
Material 
Function Total Formulae 
(mg) 
Wt. % w/w (wet 
formulae) 
Wt. % w/w (dry 
formulae) 
Calc. drug weight (mg) 
(dry tablets)
****
 
Paracetamol API
*
 810.42 58.94 81.04 249.42 
PVP
**
 Binder 100.00 7.27 10.00 30.78 
Starch Binder 83.33 6.06 8.33 25.64 
CCS
***
 Disintegrant 6.25 0.45 0.63 1.94 
Water Binder 375.00 27.27 ---- ---- 
Total ---- 1375.00 100.00 100.00 307.78 
26 
 554 
*Active Pharmaceutical Ingredient, **Polyvinylpyrrolidone ***Croscarmellose sodium ****Calculated from the 555 
average of the total paracetamol tablet weight (307.78 mg, n = 6). 556 
Table II. Paracetamol 3D printed tablet’s dimensions for different geometries of similar total weight 557 
and increased surface area and SA/V ratios.  558 
Geometry Surface area (SA) (mm2) Volume (V) (mm2) SA/V ratio Weight (mg) 
Tablet dimension (mm) 
Density (mg/mm3) 
*L×**H×***D 
Mesh 897±9.4 301±3.9 2.976±0.008 318±11.1 15.2±0.02×5.4±0.05×8.5±0.05 1.054±0.023 
Ring 449.94±2.65 369.96±3.25 1.216±0.004 323.00±1.70 15.3±0.03×5.0±0.06×8.5±0.04 0.866±0.005 
Solid 330.94±2.04 344.19±5.19 0.962±0.009 313.00±9.20 15.4±0.03×3.4±0.06×8.4±0.05 0.909±0.013 
*L=length, **H=height, ***D=diameter  559 
Table III. Fitting experimental release data, from the in vitro release of 3D printed paracetamol tablets 560 
to Zero-order, First-order, Higuchi and Korsmeyer-Peppas kinetic equations at a buffer condition (pH 561 
6.8-12 hrs).   562 
Geometry Zero order (r2) First order (r2) Higuchi (r2) Korsmeyer-Peppas (r2) n value 
Mesh 0.38 0.77 0.53 0.64 0.25 
Ring 0.67 0.96 0.84 0.91 0.44 
Solid 0.91 0.98 0.99 0.98 0.56 
 563 
 564 
 565 
Table IV. Individual paracetamol 3D printed tablet’s dimensions and their average, median, maximum, 566 
minimum dimension, standard deviation. 567 
Tablet no. 
Mesh tablets (mm) Ring tablets (mm) Solid tablets (mm) 
Length Height Width Length Height Width Length Height Width 
1 
15.24 5.42 8.50 15.01 5.13 8.30 15.39 3.50 8.35 
2 
15.21 5.51 8.47 15.33 5.08 8.47 15.40 3.46 8.47 
3 
15.20 5.40 8.38 15.38 4.94 8.50 15.34 3.36 8.46 
4 
15.22 5.46 8.51 15.30 5.07 8.40 15.36 3.52 8.33 
5 
15.26 5.45 8.53 15.26 5.09 8.42 15.26 3.38 8.42 
6 
15.19 5.49 8.47 15.16 5.06 8.38 15.37 3.42 8.45 
Average 
15.22 5.46 8.48 15.24 5.06 8.41 15.35 3.44 8.41 
Median 
15.22 5.46 8.49 15.28 5.08 8.41 15.37 3.44 8.44 
Maximum 
15.26 5.51 8.53 15.38 5.13 8.50 15.40 3.52 8.47 
27 
Minimum 
15.19 5.40 8.38 15.01 4.94 8.30 15.26 3.36 8.33 
SD 
0.03 0.04 0.05 0.13 0.06 0.07 0.05 0.06 0.06 
 568 
Table V. Individual paracetamol 3D printed tablets weight, calculated paracetamol dose/tablet, 569 
percentage deviation, and their average, median, maximum, minimum weight and standard deviation. 570 
Tablet no. 
Ring-tablet Mesh-Tablet Solid-Table 
Tablet weight 
(mg) 
Calc. para. 
dose/tablet Deviation % 
Tablet weight 
(mg) 
Calc. para. 
dose/tablet Deviation % 
Tablet weight 
(mg) 
Calc. para. 
dose/tablet Deviation % 
1 312.90 253.57 0.78 308.80 250.25 0.33 307.10 248.87 0.44 
2 318.80 258.36 2.68 300.70 243.69 -2.30 302.20 244.90 -1.16 
3 309.90 251.14 -0.19 311.90 252.76 1.34 301.30 244.17 -1.46 
4 307.70 249.36 -0.90 312.60 253.33 1.57 306.40 248.31 0.21 
5 310.80 251.87 0.10 306.00 247.98 -0.58 306.60 248.47 0.28 
6 302.80 245.39 -2.47 306.70 248.55 -0.35 310.90 251.95 1.68 
Average 310.48 251.62 0.00 307.78 249.43 0.00 305.75 247.78 0.00 
Median 310.35 251.51 -0.04 307.75 249.40 -0.01 306.50 248.39 0.25 
Maximum 318.80 258.36 2.68 312.60 253.33 1.57 310.90 251.95 1.68 
Minimum 302.80 245.39 -2.47 300.70 243.69 -2.30 301.30 244.17 -1.46 
SD 5.33 4.32 1.72 4.38 3.55 1.42 3.52 2.85 1.15 
 571 
 572 
 573 
 574 
 575 
 576 
Table VI. Individual paracetamol 3D printed tablet’s breaking force (kg and N), tensile fracture strength 577 
(MPa), and their average, median, maximum, minimum hardness and standard deviation. 578 
Tablet no. 
Mesh tablets  Ring tablets Solid tablets 
Breaking 
force (kg) 
Breaking 
force (N) 
Tensile 
strength 
(Mpa) 
Breaking force 
(kg) 
Breaking force 
(N) 
Tensile 
strength 
(Mpa) 
Breaking 
force (kg) 
Breaking 
force (N) 
Tensile 
strength 
(Mpa) 
1 2.56 25.11 2.30 2.50 24.53 2.53 8.69 85.25 19.24 
2 2.40 23.54 2.09 2.80 27.47 2.89 9.15 89.76 20.45 
3 2.70 26.49 2.47 2.50 24.53 2.73 8.71 85.45 20.59 
4 2.39 23.45 2.11 2.26 22.17 2.36 9.04 88.68 19.80 
5 2.60 25.51 2.30 2.57 25.21 2.65 8.93 87.60 20.85 
6 2.44 23.94 2.14 2.49 24.43 2.59 9.56 93.78 21.88 
28 
Average 2.52 24.67 2.24 2.52 24.72 2.63 9.01 88.42 20.47 
Median 2.50 24.53 2.22 2.50 24.53 2.62 8.99 88.14 20.52 
Maximum 2.70 26.49 2.47 2.80 27.47 2.89 9.56 93.78 21.88 
Minimum 2.39 23.45 2.09 2.26 22.17 2.36 8.69 85.25 19.24 
SD± 0.12 1.23 0.15 0.17 1.70 0.18 0.32 3.17 0.91 
 579 
Table VII. Friability of different paracetamol 3D printed geometries; mesh, ring, and solid tablets. 580 
Tablet Friability (%) Comment 
Mesh 0.65 Pass 
Ring 0.62 Pass 
Solid 0.59 Pass 
 581 
 582 
 583 
